Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Decreases By 31.4%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a large drop in short interest in January. As of January 30th, there was short interest totaling 20,320 shares, a drop of 31.4% from the January 15th total of 29,614 shares. Currently, 1.2% of the company’s shares are short sold. Based on an average daily volume of 25,094 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 25,094 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.2% of the company’s shares are short sold.

Catheter Precision Stock Performance

Catheter Precision stock traded up $0.16 on Friday, reaching $1.43. 1,150,589 shares of the stock were exchanged, compared to its average volume of 101,467. The firm has a fifty day moving average price of $2.04 and a two-hundred day moving average price of $2.38. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.20. Catheter Precision has a twelve month low of $1.14 and a twelve month high of $15.68.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($26.60) by $24.90. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $1.20 million. Catheter Precision had a negative return on equity of 208.54% and a negative net margin of 2,333.29%. As a group, analysts expect that Catheter Precision will post -8.9 earnings per share for the current fiscal year.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.